Education
About Us
Working with TipRanks
Follow Us
medmix AG (CH:MEDX)
:MEDX
Top Page
medmix AG (MEDX) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF436.56M
Dividend Yield4.72%
Average Volume (3M)40.49K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS GrowthN/A
CountryCH
EmployeesN/A
SectorHealthcare
Sector Strength41
IndustryN/A
Share Statistics
EPS (TTM)0.39
Shares Outstanding41,262,370
10 Day Avg. Volume40,014
30 Day Avg. Volume40,491
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio22.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
medmix AG Business Overview & Revenue Model
Company Description
How the Company Makes Money
medmix AG Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 479.70M | 483.90M | 486.60M | 477.10M | 457.30M | 351.30M | Gross Profit |
| 156.30M | 159.70M | 157.70M | 175.40M | 181.20M | 121.10M | EBIT |
| 14.00M | 12.90M | 16.00M | 19.60M | 59.90M | 18.10M | EBITDA |
| 75.70M | 67.30M | 71.40M | 68.30M | 110.60M | 60.90M | Net Income Common Stockholders |
| -1.80M | -7.40M | 300.00K | 11.60M | 44.00M | 9.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 79.30M | 96.20M | 130.60M | 316.80M | 210.00M | 46.20M | Total Assets |
| 697.00M | 954.20M | 1.01B | 1.11B | 974.40M | 789.90M | Total Debt |
| 276.60M | 323.40M | 349.70M | 473.50M | 320.90M | 332.30M | Net Debt |
| 272.10M | 227.20M | 219.10M | 160.00M | 111.10M | 317.50M | Total Liabilities |
| 401.90M | 507.50M | 532.40M | 601.10M | 440.50M | 456.50M | Stockholders Equity |
| 295.10M | 436.40M | 465.40M | 504.80M | 533.90M | 333.40M |
| Cash Flow | Free Cash Flow | ||||
| 19.20M | 38.10M | 3.20M | 9.00M | 55.40M | 7.50M | Operating Cash Flow |
| 69.30M | 86.60M | 56.10M | 47.60M | 87.30M | 50.60M | Investing Cash Flow |
| -88.60M | -51.50M | -80.60M | -57.00M | -3.30M | 4.40M | Financing Cash Flow |
| 15.20M | -48.60M | -153.80M | 116.10M | 111.60M | -42.90M |
medmix AG Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CHF436.56M | ― | 4.72% | ― | ― | |||
75 Outperform | CHF613.65M | 7.87 | ― | 32.30% | 631.04% | ||
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
| $3.29B | 41.43 | 20.81% | 0.48% | ― | ― | ||
| $2.55B | 32.91 | 4.84% | 1.74% | ― | ― | ||
| €365.56M | 16.54 | 13.13% | 2.29% | ― | ― | ||
| CHF1.05B | 289.13 | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CH:MEDX
medmix AG
10.58
-4.54
-30.03%
CH:BSLN
Basilea Pharmaceutica
50.40
8.90
21.45%
MEDGF
Medacta Group SA
164.33
26.53
19.25%
TCHBF
Tecan Group AG
200.00
-149.48
-42.77%
DE:283
IVF HARTMANN Holding AG
148.00
18.66
14.43%
CH:MED
Medartis Holding AG
77.40
4.20
5.74%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.